Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer
Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.
Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer
April 3rd 2017David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.
Many Challenges Loom in Ensuring Validity and Utility of Diagnostic Tests
May 12th 2015While diagnostic tests play a critical role in physician decision making-particularly in oncology-questions remain regarding the clinical utility of some of these tests, as well as the validity of laboratory-developed tests.
Chasing CTCs: Novel Technologies May Unlock Potential of Elusive Biomarker
October 28th 2014Despite being discovered more than 150 years ago, tumor cells present in the blood of patients with cancer are only now inspiring significant research efforts. Technological advancements have allowed the isolation and enrichment of these rare cells and, as potential metastatic "emissaries," they have significant potential for improving the detection and treatment of advanced and possibly even early-stage disease.